RenovaCare’s SkinGun uses a patient’s own stem cells to heal their wounds faster and more efficiently than a traditional skin graft. Pennsylvania state police officer Matthew Uram suffered severe second-degree burns to his face, right arm and leg after a friend’s bonfire got out of control. Uram was facing months of painful skin grafts, the […]
Wound Care
Origin treats first patients in study of nitric oxide for diabetic foot ulcers
Origin said today that it treated the 1st patients in its dose-ranging Genesis Phase IIb-equivalent trial. The study is evaluating therapeutic quantities of plasma-generated nitric oxide as a treatment for chronic diabetic foot ulcers. The 27-week trial is slated to enroll up to 100 patients. Patients will be randomized into 1 of 4 dosing regimens, […]
Integra LifeSciences closes $200m Derma Sciences buy
Integra LifeSciences (NSDQ:IART) said today that it closed its $205 million buy of Derma Sciences (NSDQ:DSCI) and its line of wound care products. The $7-per-share deal included a line of regenerative allograft products derived from human placental tissue that Derma Sciences acquired when it paid nearly $80 million for BioD last year. Integra also agreed to pay $32 per share […]
Tissue Regenix expands, launches DermaPure in US
Tissue Regenix said today it expanded its operations to the US, now offering its DermaPure product for chronic and acute wound care indications in the region. The U.K.-based company’s dCell decellularization technology is a multi-tissue regenerative medical platform designed for use in a number of applications to allow the body to regenerate critical tissue through […]
E-Qure wins FDA nod to expand chronic wound treatment device trial
Chronic wound treatment device developer E-Qure said today it won FDA approval to expand and launch a pivotal trial of its Bio-electrical Signal Therapy Device chronic wound treatment device. The New York-based company said its Bio-electrical Signal Therapy device is designed for non-invasively treating hard-to-heal chronic wounds, including pressure ulcers, diabetic foot ulcers, venous stasis ulcers and […]
AcelRx touts Dsuvia data for burn victims
AcelRx Pharmaceuticals (NSDQ:ACRX) said today that it plans to present data from a study evaluating its Dsuvia pain reliever in patients with moderate-to-severe acute pain resulting from trauma or injury. The company’s Dsuvia candidate is composed of 30 sufentanil tablets delivered sublingually using a disposable, pre-filled single-dose applicator. Dsuvia is investigational and not approved in […]
Smith & Nephew misses the mark with 2016 results
Smith & Nephew (NYSE:SNN) today posted 2016 numbers that missed the consensus forecast, sending share prices down today in London and New York despite a net profit gain of more than 91%. Europe’s largest large-joint implant maker reported 2016 trading profits of $1.02 billion, off by -7.2% compared with 2015, on 0.8% sales growth to $4.67 billion. […]
7 medical device industry suppliers you need to visit at MD&M West 2017
More than 20,000 engineers and executives are heading to Anaheim, Calif., this week for MD&M West—which its creator UBM bills as the world’s largest annual medical device manufacturing event. The event boasts a multitude of medical device–related products and services, ranging from co-extrusion to metal cleaning fluids. They are also a tungsten supplier to use for medical […]
Allergan closes $3B Acelity LifeCell buy
Acelity said today that it closed the sale of its regenerative medicine unit, LifeCell, to Allergan (NYSE:AGN) for $2.9 billion in cash. The deal brings LifeCell’s regenerative medicine and reconstructive portfolio to Allergan, joining a portfolio of medical aesthetics, breast implant and tissue expander product lines. Dublin-based Allergan said it expects to bring in $450 million in revenue this year, growing […]
MediWound touts Phase II study
MediWound (NSDQ:MDWD) touted data from a phase II trial of its EscharEx topical biological drug for debridement of chronic and other hard-to-heal wounds. The data includes a follow-up period of 6 months from the last treatment to 3 months from wound closure. The randomized phase II trial enrolled 73 patients with a variety of chronic […]
How Acelity plans to disrupt fee-for-service to build a value-based business
Value-based care is disrupting the old fee-for-service models in the U.S. healthcare industry, and medical device makers must adapt or perish. Here’s how wound care company Acelity is responding. The rise of value-based care in the U.S. is causing a major shift in the medical device industry. Health provider customers want to know how medical […]